Crinone

Amenorrhea, hormonal imbalance, prophylaxis of recurrent spontaneous preterm birth + 9 more

Treatment

20 Active Studies for Crinone

What is Crinone

Progesterone

The Generic name of this drug

Treatment Summary

Progesterone is a naturally-occurring hormone in women that helps with fertility and pregnancy. Low levels of progesterone or a lack of a response to progesterone can lead to infertility or pregnancy loss. Progesterone is also used in various contraceptive preparations to stop ovulation and fertilization. It is available in different forms, such as capsules, gel, tablets, inserts, and injections. Progesterone can be made from plants and is chemically identical to the progesterone found in the human body.

Progesterone

is the brand name

image of different drug pills on a surface

Crinone Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Progesterone

Progesterone

1978

124

Effectiveness

How Crinone Affects Patients

Progesterone has many different effects, depending on the concentration and delivery form of the drug. Generally, it helps to transition the uterus from the growth phase to the preparation phase needed for pregnancy. It also helps to provide a supportive environment for a fertilized egg and maintain a pregnancy. Progesterone can also be used as a contraceptive, as it suppresses ovulation, thickens cervical mucus to prevent sperm movement, and lowers the levels of hormones that trigger ovulation. Injections of progesterone are used to help prevent overgrowth of endometrial tissue due to unopposed estrogen, which can

How Crinone works in the body

Progesterone helps prepare the uterus for pregnancy. It works by activating a special protein, called Progesterone Receptor (PR), which is found in female reproductive tissue and the central nervous system. This protein helps control the growth and development of target tissues. Progesterone can also help prevent pregnancy by thickening cervical mucus and stopping ovulation. When taken perfectly, it has a failure rate of 0.5%. However, when taken regularly, the failure rate is estimated to be 5%.

When to interrupt dosage

The suggested dosage of Crinone is contingent upon the determined condition, such as hormonal imbalance, Female Infertility and Postmenopause. The amount of dosage is contingent upon the method of administration noted in the table beneath.

Condition

Dosage

Administration

recurrent spontaneous preterm birth

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Reproductive Technology

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Endometrial Hyperplasia

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Amenorrhea

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

hormonal imbalance

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Postmenopause

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Hysterectomy

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Amenorrhea

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Uterine hemorrhage

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Vasomotor System

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Hot flashes

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

prophylaxis of recurrent spontaneous preterm birth

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Warnings

Crinone Contraindications

Condition

Risk Level

Notes

Liver Diseases

Do Not Combine

Thromboembolism

Do Not Combine

suspected pregnancy

Do Not Combine

Pulmonary Embolism

Do Not Combine

Stroke

Do Not Combine

Cerebrovascular accident

Do Not Combine

Thrombophlebitis

Do Not Combine

Breast

Do Not Combine

Deep Vein Thrombosis

Do Not Combine

Pulmonary Embolism

Do Not Combine

Pulmonary Embolism

Do Not Combine

Breast Cancer

Do Not Combine

Deep Vein Thrombosis

Do Not Combine

Breast

Do Not Combine

Breast

Do Not Combine

undiagnosed abnormal genital bleeding

Do Not Combine

suspected pregnancy

Do Not Combine

Thromboembolism

Do Not Combine

Malignant Neoplasms

Do Not Combine

Stroke

Do Not Combine

undiagnosed vaginal bleeding

Do Not Combine

Abortion, Spontaneous

Do Not Combine

Venous Thrombosis

Do Not Combine

Thrombophlebitis

Do Not Combine

Stroke

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Progesterone may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Progesterone may interact with Pulse Frequency

There are 20 known major drug interactions with Crinone.

Common Crinone Drug Interactions

Drug Name

Risk Level

Description

Amitriptyline

Major

The metabolism of Amitriptyline can be decreased when combined with Progesterone.

Amoxapine

Major

The metabolism of Amoxapine can be decreased when combined with Progesterone.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Progesterone.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Progesterone.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Progesterone.

Crinone Toxicity & Overdose Risk

The toxic dose of progesterone in rats is 327mg/kg. It is not recommended to use progesterone while pregnant and it may decrease fertility until it is stopped. Studies have found that progesterone may cause tumors in animals, but it is not yet known if this applies to humans. Using combined oral contraceptives has been linked to an increased risk of breast cancer, but it is not clear if progestin-only contraceptives have the same effect. Progesterone can be found in the milk of nursing mothers, but there have been no reports of negative effects on the baby. In rare cases, there have been reports

image of a doctor in a lab doing drug, clinical research

Crinone Novel Uses: Which Conditions Have a Clinical Trial Featuring Crinone?

Presently, there are 56 active clinical trials assessing the ability of Crinone Gel to aid Assisted Reproductive Techniques (ART) and Reproductive Technology.

Condition

Clinical Trials

Trial Phases

Endometrial Hyperplasia

0 Actively Recruiting

Postmenopause

5 Actively Recruiting

Phase 2, Not Applicable

recurrent spontaneous preterm birth

0 Actively Recruiting

Uterine hemorrhage

0 Actively Recruiting

hormonal imbalance

0 Actively Recruiting

Vasomotor System

0 Actively Recruiting

Amenorrhea

0 Actively Recruiting

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3

Reproductive Technology

2 Actively Recruiting

Not Applicable

Amenorrhea

0 Actively Recruiting

prophylaxis of recurrent spontaneous preterm birth

0 Actively Recruiting

Hysterectomy

3 Actively Recruiting

Phase 3, Not Applicable

Crinone Reviews: What are patients saying about Crinone?

5

Patient Review

10/15/2007

Crinone for Infertility caused by Deficiency of a Hormone-Progesterone

4.3

Patient Review

3/13/2012

Crinone for Infertility caused by Deficiency of a Hormone-Progesterone

I've been using this for a little over a week and have experienced fatigue and some breast tenderness. I also have mild cramping in my vaginal area, but it's not too bad. I'm unsure if it's okay to have intercourse while taking this drug because of the discharge.

4.3

Patient Review

5/24/2010

Crinone for Infertility caused by Deficiency of a Hormone-Progesterone

I had some uncomfortable side effects while taking this medication, including breast tenderness, cramping, heartburn and acne.

4

Patient Review

7/28/2010

Crinone for Infertility caused by Deficiency of a Hormone-Progesterone

I've had good results with this progesterone supplement, and it has far fewer side effects than other brands. The discharge can be a bit icky, and my breasts are sometimes sore, but that's it.

4

Patient Review

1/7/2010

Crinone for Infertility caused by Deficiency of a Hormone-Progesterone

The side effects for me were really bad. I had headaches, was dizzy, and got cramps in my stomach.

3.7

Patient Review

5/30/2009

Crinone for Infertility caused by Deficiency of a Hormone-Progesterone

I'm very drug sensitive, and this unfortunately did not work for me. The side effects weren't worth it either.

3

Patient Review

1/16/2010

Crinone for Infertility caused by Deficiency of a Hormone-Progesterone

I'm just starting out with this treatment, but I'm already seeing some positive results. My monthly cycles have become more regular, and I haven't experienced any terrible side effects. Just some minor headaches, breast tenderness, and discharge.

Patient Q&A Section about crinone

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Crinone gel help implantation?

"The study found that the use of Crinone 8% vaginal progesterone gel was associated with a lower implantation rate than the use of IM progesterone-in-oil."

Answered by AI

What is the purpose of Crinone gel?

"This medication is used to treat infertility by increasing the levels of progesterone in the body. Progesterone is a hormone essential for maintaining pregnancy. This medication can also be used to restore menstrual cycles in women whose cycles have stopped."

Answered by AI

What is Crinone used for in IVF?

"Crinone is a medication used to treat infertility by providing extra progesterone. This is necessary when the body does not produce the correct levels of progesterone during the menstrual cycle, or when undergoing assisted fertility procedures. Crinone may also be used during pregnancy to support the new pregnancy."

Answered by AI

How long do you take Crinone during pregnancy?

"Crinone 8% is given vaginally as two 90 mg doses per day to women with partial or complete ovarian failure who need progesterone replacement. If pregnancy happens, treatment may continue until the placenta can function on its own, for up to 10 to 12 weeks."

Answered by AI

Clinical Trials for Crinone

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada

The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.

Phase 4
Recruiting

Erevna Innovations Inc.

Andreas Nikolis, MD, PhD

Image of Shady Grove Fertility Rockville in Rockville, United States.

ICSI vs IVF for Female Infertility

Any Age
Female
Rockville, MD

The goal of this clinical trial is to learn whether two different methods of helping eggs and sperm join-intracytoplasmic sperm injection (ICSI) and conventional in vitro fertilization (IVF)-lead to better embryo development when using frozen donor sperm in people who do not have male fertility problems. The main questions it aims to answer are: Does one method create more usable embryos (blastocysts) than the other? Is there a difference in how often fertilization does not happen at all? Do either of the methods lead to better embryo quality or early pregnancy? Participants will: Have their eggs divided into two groups. One group will be fertilized using ICSI (where a sperm is injected directly into an egg), and the other using conventional IVF (where eggs are mixed with sperm in a dish). The fertilization method for each egg will be randomly assigned, with a random process also used to determine the assignment of any extra egg when an odd number is collected. Continue regular fertility treatment while the study team compares the results of each fertilization method. This study includes people with non-male factor infertility and uses frozen donor sperm. It hopes to learn whether ICSI, which is often used even when it may not be needed, truly helps improve outcomes compared to conventional IVF in these cases.

Recruiting
Has No Placebo

Shady Grove Fertility Rockville

Kate Devine, MD

Have you considered Crinone clinical trials?

We made a collection of clinical trials featuring Crinone, we think they might fit your search criteria.
Go to Trials

Have you considered Crinone clinical trials?

We made a collection of clinical trials featuring Crinone, we think they might fit your search criteria.
Go to Trials
Image of Don tyson Center for Agricultural Sciencers in Fayetteville, United States.

Protein and Exercise for Postmenopausal Women

Any Age
Female
Fayetteville, AR

The goal of this clinical trial is to learn if consuming a higher protein diet that includes one serving of beef each day, in combination with resistance exercise, improves wellbeing in postmenopausal women. It will also tell us about how higher protein intake changes body composition and blood values related to health. The main questions it aims to answer are: * Does higher protein intake combined with resistance training improve mood and sleep in postmenopausal women? * What other health benefits to postmenopausal women experience when the follow a higher protein diet and participate in resistance exercise? Researchers will compare three groups 1) postmenopausal women living their daily lives as usual, 2) postmenopausal women consuming a higher protein diet, and 2) postmenopausal women consuming a higher protein diet and participating in resistance training. Participants will: * Consume a higher protein diet for 16 weeks * Participate in an at-home resistance training for 16 weeks * Keep a diary of their food intake, sleep habits, and mood * Have health assessments every 4 weeks

Recruiting
Has No Placebo

Don tyson Center for Agricultural Sciencers (+1 Sites)

Jamie Baum

Image of The Buck Institute for Research on Aging in Novato, United States.

GLYLO Supplement for Postmenopausal Aging

45 - 65
Female
Novato, CA

The aim of this study is to assess the effectiveness of GLYLO, a dietary supplement, in postmenopausal women aged 45 to 65 who are overweight or obese and have elevated HbA1c levels. Specifically, the study seeks to evaluate whether GLYLO can reduce advanced glycation end products (AGEs) levels, which are harmful compounds formed when sugar attaches to proteins or fats in the body and can contribute to aging and disease. The primary outcome of the study is to determine if GLYLO reduces AGEs, enhances metabolic and hormonal health, and mitigates age-related functional decline. This study includes one screening visit and three testing visits over a 6-month period. After eligibility is confirmed, participants will be randomly assigned to one of two groups to take either GLYLO (two capsules daily) or a placebo at home for 24 weeks. Participants will provide blood samples at every visit. During the three testing visits, they will complete physical performance and cognitive function tests, provide both blood and urine samples, and fill out quality of life and 24-hour dietary intake questionnaires. The dietary intake questionnaires will be completed only twice i.e. at the baseline visit and again at the final 6-month visit.

Recruiting
Advanced

The Buck Institute for Research on Aging

Image of Noll Laboratory in University Park, United States.

Estradiol and Elagolix for Menopause

42 - 64
Female
University Park, PA

The frequency and severity of heat waves has increased in the last decades. Older adults (over 65 years) have impaired responses to heat stress making them at increased risk for adverse events. Previous heat waves report that women over 65 experience worse health outcomes than any other age group and age matched men. Aging and reproductive hormones, specifically estrogen, independently alter responses to heat stress. However, the combined effects of low estrogen following menopause and aging on the response to heat stress are unknown. In this study, the investigators will identify the role of estrogen in pre and post menopausal women on thermoregulatory responses to heat stress.

Phase 4
Recruiting

Noll Laboratory

W. Larry Kenney, Ph.D.

Have you considered Crinone clinical trials?

We made a collection of clinical trials featuring Crinone, we think they might fit your search criteria.
Go to Trials